IFNA14 (interferon alpha 14) encodes a type I interferon with antiviral and immunomodulatory functions. As a member of the interferon alpha gene family, IFNA14 is involved in immune system activation and cytokine signaling pathways, with expression patterns linked to disease susceptibility and treatment responses 1. The gene demonstrates genetic polymorphism within populations, though with lower variability than initially expected 2. IFNA14 expression is associated with various pathological conditions: co-deletion with CDKN2A occurs in 44% of glioblastomas and correlates with poor survival outcomes 3, while tubulointerstitial expression of related type I interferons like IFNA5 associates with proteinuria in lupus nephritis 4. In cardiovascular disease, IFNA16/IFNA14 variants serve as independent risk factors for distinguishing between different cardiomyopathy types 5. Functionally, IFNA14 upregulation occurs in response to viral infection and contributes to broad antiviral immune responses 6. Additionally, genetic variants in the IFNA7/IFNA14 region influence colorectal cancer survival outcomes 7, and IFNA14 expression changes during sinecatechins treatment of HPV-associated genital warts, particularly in virological responders 8.